No Data
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
Hong Kong stocks unusual movement | Beigene (06160) rose nearly 3% intraday as PRMT5 inhibitors approved for clinical use in China, expecting intensive catalysis next year.
Beigene (06160) rose nearly 3% during the session, as of the time of writing, it rose by 2.29%, closing at 120.5 Hong Kong dollars, with a turnover of 0.14 billion Hong Kong dollars.
China ADRs Have Increased to the Largest Share Since Late 2021 – GS
BeiGene Announces U.S. Regulatory Filing
Labcorp Holdings Names Julia Wang Chief Financial Officer, Effective Dec. 2 >LH
Press Release: Labcorp CFO Glenn Eisenberg Announces Plans to Retire
No Data
No Data
